WO2008101671A3 - PROTÉINES HYBRIDES IL4-Fc - Google Patents

PROTÉINES HYBRIDES IL4-Fc Download PDF

Info

Publication number
WO2008101671A3
WO2008101671A3 PCT/EP2008/001293 EP2008001293W WO2008101671A3 WO 2008101671 A3 WO2008101671 A3 WO 2008101671A3 EP 2008001293 W EP2008001293 W EP 2008001293W WO 2008101671 A3 WO2008101671 A3 WO 2008101671A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion proteins
domain
relates
constant immunoglobulin
polypeptide
Prior art date
Application number
PCT/EP2008/001293
Other languages
English (en)
Other versions
WO2008101671A2 (fr
WO2008101671A9 (fr
Inventor
Oliver Hill
Christian Gieffers
Meinolf Thiemann
Original Assignee
Apogenix Gmbh
Oliver Hill
Christian Gieffers
Meinolf Thiemann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Gmbh, Oliver Hill, Christian Gieffers, Meinolf Thiemann filed Critical Apogenix Gmbh
Publication of WO2008101671A2 publication Critical patent/WO2008101671A2/fr
Publication of WO2008101671A3 publication Critical patent/WO2008101671A3/fr
Publication of WO2008101671A9 publication Critical patent/WO2008101671A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

L'invention concerne des protéines hybrides comprenant au moins un domaine polypeptidique d'IL-4 et un domaine constant d'immunoglobuline.
PCT/EP2008/001293 2007-02-19 2008-02-19 PROTÉINES HYBRIDES IL4-Fc WO2008101671A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07003443 2007-02-19
EP07003443.4 2007-02-19

Publications (3)

Publication Number Publication Date
WO2008101671A2 WO2008101671A2 (fr) 2008-08-28
WO2008101671A3 true WO2008101671A3 (fr) 2008-12-11
WO2008101671A9 WO2008101671A9 (fr) 2009-02-19

Family

ID=39670915

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/001293 WO2008101671A2 (fr) 2007-02-19 2008-02-19 PROTÉINES HYBRIDES IL4-Fc

Country Status (1)

Country Link
WO (1) WO2008101671A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623693B (zh) * 2017-03-20 2022-03-25 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102201694B1 (ko) * 2012-07-18 2021-01-12 아포게닉스 아게 CD95-Fc 이소형의 혼합물을 포함하는 조성물
CA2925417C (fr) * 2013-09-24 2023-10-24 Fahar Merchant Proteines de fusion se liant au recepteur de l'interleukine 4 et utilisations associees
EP3630162A1 (fr) * 2017-05-24 2020-04-08 Novartis AG Protéines greffées anticorps-cytokine et méthodes d'utilisation
EP4285913A1 (fr) * 2022-05-30 2023-12-06 Ecole Polytechnique Fédérale de Lausanne (EPFL) Thérapie de lymphocytes t adoptive hautement efficace

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US6130318A (en) * 1994-07-01 2000-10-10 Bayer Aktiengellschaft hIL-4 mutant proteins used as antagonists or partial agonists of human interleukin 4
WO2001003737A1 (fr) * 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Proteines de fusion d'immunoglobine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130318A (en) * 1994-07-01 2000-10-10 Bayer Aktiengellschaft hIL-4 mutant proteins used as antagonists or partial agonists of human interleukin 4
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
WO2001003737A1 (fr) * 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Proteines de fusion d'immunoglobine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PICCIRILLO C ET AL: "Prevention of experimental allergic encephalomyelitis by intramuscular gene transfer with cytokine-encoding plasmid vectors", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 10, 10 August 1999 (1999-08-10), pages 1915 - 1922, XP002202211, ISSN: 1043-0342 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623693B (zh) * 2017-03-20 2022-03-25 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用

Also Published As

Publication number Publication date
WO2008101671A2 (fr) 2008-08-28
WO2008101671A9 (fr) 2009-02-19

Similar Documents

Publication Publication Date Title
HK1219490A1 (zh) 免疫球蛋白融合蛋白
WO2012142515A3 (fr) Protéines hybrides fc comprenant de nouveaux lieurs ou agencements
WO2008030558A3 (fr) Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations
BRPI0807480A2 (pt) Ligando, imunoglobulina g, composição e proteína de fusão
WO2004085478A3 (fr) Proteines hybrides fc ameliorees
WO2006105062A3 (fr) Régions fc d'anticorps altérées et utilisations de celles-ci
WO2007060117A3 (fr) Proteines effectrices chimeres se liant a la keratine
WO2009067636A3 (fr) Polypeptides d'insuline modifiés et leurs utilisations
EP1866340A4 (fr) Fragment fc d'immunoglobuline modifié par un polymère non peptidique et composition pharmaceutique contenant ce fragment fc
WO2006105338A3 (fr) Variants fc presentant des proprietes optimisees
WO2006031370A3 (fr) Variants de polypeptides dotes d'une fonction effectrice modifiee
IL222924A0 (en) Albumin fusion proteins
IL196889A0 (en) Albumin-insulin fusion proteins
IL197580A0 (en) Albumin fusion proteins
WO2008092117A3 (fr) Nouvelles insertions, délétions et substitutions d'immunoglobulines
EP2211888A4 (fr) Protéines de fusion d'albumine
ZA200702004B (en) Binding domain fusion proteins
IL189246A0 (en) Albumin fusion proteins
EP1934372A4 (fr) Proteines hybrides ssb-polymerase
EP1877437A4 (fr) Protéines chimériques possédant des domaines de liaison à phosphatidylsérine
EP1985961B8 (fr) Elément de blindage composite
WO2008100470A3 (fr) Protéines de fusion de l'immunoglobuline et procédés de fabrication
EP2177546A4 (fr) Matiere de resine pour des objectifs optiques et element optique utilisant celle-ci
WO2008101671A3 (fr) PROTÉINES HYBRIDES IL4-Fc
EP3976642A4 (fr) Anticorps apoe, protéines de fusion et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08734585

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08734585

Country of ref document: EP

Kind code of ref document: A2